Clicky

Unicycive Therapeutics, Inc.(UNCY)

Description: Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.


Keywords: Medicine Biotechnology Kidney Disease Kidney Acute Kidney Injury Organ Failure Hyperphosphatemia Chemical Entity

Home Page: www.unicycive.com

UNCY Technical Analysis

4300 El Camino Real
Los Altos, CA 94022
United States
Phone: 650 351 4495


Officers

Name Title
Dr. Shalabh K. Gupta M.D., MPA Founder, Chairman, CEO & Pres
Mr. John W. Townsend CPA Chief Financial Officer
Dr. Pramod Gupta Ph.D. Exec. VP of Pharmaceutical & Bus. Operations
Mr. Douglas Jermasek M.B.A. Exec. VP of Corp. Strategy

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.4394
Price-to-Sales TTM: 11.184
IPO Date: 2021-07-12
Fiscal Year End: December
Full Time Employees: 9
Back to stocks